Peer-reviewed veterinary case report
Miltefosine treatment reduces symptoms of canine leishmaniosis in 56
By Woerly, Virginie et al.·Published in Parasitology research·2009·R&D, France·View original on PubMed →
PetCaseFinder translated the abstract of this peer-reviewed paper into plain English so pet owners can read it. We do not publish original research — every detail traces back to the citation above. How we work →
Original publication title: Clinical efficacy and tolerance of miltefosine in the treatment of canine leishmaniosis.
- Species:
- dog
Plain-English summary
A group of 96 dogs with leishmaniosis, a disease caused by parasites, were treated with an oral medication called miltefosine for 28 days. The treatment led to a significant improvement in their symptoms, with a 61.2% reduction in clinical signs by the end of the study. Most dogs showed positive responses, with veterinarians noting that 82.7% had better results than with other treatments. Some dogs experienced mild side effects like vomiting, but these were temporary and not serious. Overall, miltefosine was found to be both safe and effective for treating this condition in dogs.
People also search for: dog leishmaniosis treatment · miltefosine for dogs · dog vomiting after medication
Abstract
The study was aimed to assess the efficacy and tolerance profiles of an oral administration miltefosine drug (Milteforan(R), Virbac) in dogs with natural leishmaniosis. In this multicentric open trial, 96 dogs were treated with the drug administered orally at a dose of 2 mg/kg body weight once a day for 28 days. During the 56-day trial, clinical signs of the dogs were monitored every 2 weeks. On the first and the last visits, blood and bone marrow samples were collected for laboratory analyses. According to clinical scores, the treatment demonstrated a significant time-dependent therapeutic effect resulting in a 61.2% mean reduction on day 56. Hematologic and biochemical analyses showed improvements in most of the parameters examined, supporting the observed clinical efficacy of the drug. Overall, veterinarians estimated that 82.7% of the dogs treated with the miltefosine drug showed an equal or higher treatment efficacy than other antileishmanial drugs. During the trial, the adverse reactions probably associated with the drug treatment were observed in 11.7% of the dogs. However, they were not serious. The most frequent one was vomiting, which was transient, self-limiting, and reversible. These data demonstrate that the drug, at the recommended dose and treatment regime, was safe and efficacious for the treatment of canine leishmaniosis.
Find similar cases for your pet
PetCaseFinder finds other peer-reviewed reports of pets with the same symptoms, plus a plain-English summary of what was tried across them.
Search related cases →Original publication on PubMed: https://pubmed.ncbi.nlm.nih.gov/19322588/